NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. - Wikidata - awgldk - TriplyDB

NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.

NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.

http://www.wikidata.org/entity/Q41815541

about

A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor A Fluorescence-Guided Laser Ablation System for Removal of Residual Cancer in a Mouse Model of Soft Tissue Sarcoma.Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma.The NF1 gene revisited - from bench to bedside.Targeted therapy in sarcomas other than GIST tumors Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182.Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.Modeling RASopathies with Genetically Modified Mouse Models.The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.Methods to generate genetically engineered mouse models of soft tissue sarcoma.Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.Genomics of a pediatric ovarian fibrosarcoma. Association with the DICER1 syndrome.NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response.RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma.

P2860

Q27003534-67DA1F29-F987-45ED-92DC-4A2F7D8B637D Q30391185-099B3C51-4EB2-4CF6-9F8D-3B064A586A12 Q33688908-13ABDDF9-BB53-4D4C-9C23-65D31E484661 Q33737662-58F03A72-C9AA-4E46-8F14-A89F744A8691 Q33899910-D65198F2-CF95-485E-9187-BB78109E34DF Q34227509-4E846DCA-B514-4CE8-9317-081EAD0EAC99 Q35622367-9D2D6CEF-85C1-483D-9087-0836D5AEBF41 Q35788976-238A1A2C-E8A5-4A52-BFC0-4879F7D02C69 Q36100460-6CD82175-176B-419D-9D82-A13D70D71466 Q36145645-AA422310-2E08-43D0-BACA-80D7D9B671BF Q37408543-F8897B43-F454-4992-BCAC-79B6BAA53ED0 Q37619722-DB1440A6-9B69-46FB-8932-71E0A343D2E3 Q38636749-5A2313DB-4817-4ACE-A969-B2E34EF1EC3E Q39030536-D71B2FEF-9B46-4EFA-AF32-0D313CE8EA13 Q39031139-23DF52C2-5323-4BC9-882E-8F43DB425E52 Q39045958-769ECDDC-2554-4086-B714-A0005C46E138 Q41693158-A2D02914-22C9-47A2-B68C-4C343D2252F8 Q42572216-F182836C-E31D-4504-9DB3-1DA59C36A0EB Q47144771-6B0C9257-7DA0-4920-A200-2B5CC159FAD2 Q49830155-B1649F0A-4547-4A95-B375-319FDAC5263C Q51840300-53946260-C469-41AB-AAF8-0002EF6A7A86 Q53478339-E73083EE-87EB-493F-93A7-1AFC1950C702 Q54239575-F3E7B338-87C7-4213-B350-D880E26684BA

P2860

NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.

http://www.wikidata.org/entity/Q41815541

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

NF1 deletion generates multipl ...... hat respond to MEK inhibition.

@en

type

label

NF1 deletion generates multipl ...... hat respond to MEK inhibition.

@en

prefLabel

NF1 deletion generates multipl ...... hat respond to MEK inhibition.

@en

P1433

Q41815541-B8BFBB15-45D3-475B-AEA8-81211EEC399F

P1476

Q41815541-E792EF8A-791F-4D75-97DB-038A875DB561

P2093

Q41815541-5E4911A6-3B95-4847-B2BA-75FAAB5CF328

Q41815541-62547580-E2CA-4738-91A3-BC017D2EEFEA

Q41815541-8310B78B-0303-49C6-982F-14B80C248438

Q41815541-83898D99-CCA9-4B0C-A0D4-D0F8C7AB716E

Q41815541-B411F748-BC46-42A4-BEDD-5066B7444739

Q41815541-BB674CF5-7E21-47EF-BF8B-3AC316A2453D

Q41815541-C814379F-8F68-4F52-8FAC-5DD5E26D7BD1

Q41815541-F2D5B92B-2A33-4BB6-9383-961A2D0B4D08

P2860

Q41815541-0104A223-0041-4F40-B54A-D8095B8EEC5B

Q41815541-09C057FB-3979-4F49-9D10-81719505642D

Q41815541-0E3BC62F-E3D4-4383-AF11-A4E1987D5A05

Q41815541-16B0B60A-D8C2-4417-9F15-B7E6856A4004

Q41815541-16D572A4-2F0F-4BBD-9E72-1E96CCB500BF

Q41815541-1E908C0B-844B-4F0F-B191-8AAD233D3A3B

Q41815541-2366677A-E66F-4C9C-91CE-21A1BC43A2BF

Q41815541-240C8D01-E2DE-4869-A4A9-F2D9DA4E64B2

Q41815541-260B8FF4-9A79-4B17-98AD-572A0F27E739

Q41815541-26285B5D-A8E5-41FA-9751-F0B132A8E2AD

P304

Q41815541-98666F1A-E64E-41B8-AE2E-E09B5ECFE4E4

P31

Q41815541-E21EE31E-05DC-4281-BB3D-6D6E06406DCA

P356

Q41815541-19CF3200-A85D-4B21-A5C0-25A6D917737E

P433

Q41815541-6CCB6D51-42B0-46F6-BA07-4976E34347AB

P478

Q41815541-C2A8C222-8520-4520-AD5A-DD6E8ED1FF6C

P50

Q41815541-AE9D110A-4C5F-4D20-AA08-67F4CCA1CAE2

P577

Q41815541-F506B68D-283D-4DBB-9D83-A4C000C82328

P698

Q41815541-39BEA20C-C0C0-448D-98B2-8CD63F8CEE1A

P932

Q41815541-20925F7D-4F82-44D5-9ADB-387E59A4C580

P356

1535-7163.MCT-13-0189

P1433

Molecular Cancer Therapeutics

P1476

NF1 deletion generates multipl ...... that respond to MEK inhibition

@en

P2093

David G Kirsch

http://www.w3.org/2001/XMLSchema#string

Jeffrey K Mito

http://www.w3.org/2001/XMLSchema#string

Leslie Dodd

http://www.w3.org/2001/XMLSchema#string

Mohit Sachdeva

http://www.w3.org/2001/XMLSchema#string

Rebecca D Dodd

http://www.w3.org/2001/XMLSchema#string

Rhea Chitalia

http://www.w3.org/2001/XMLSchema#string

William C Eward

http://www.w3.org/2001/XMLSchema#string

Yan Ma

http://www.w3.org/2001/XMLSchema#string

P2860

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain

Mouse models of tumor development in neurofibromatosis type 1

Mouse tumor model for neurofibromatosis type 1

Molecular mechanisms and clinical applications of angiogenesis

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling.

Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors

P304

1906-1917

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-13-0189

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Jordi Barretina

P577

2013-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23858101

http://www.w3.org/2001/XMLSchema#string

P932

3825462

http://www.w3.org/2001/XMLSchema#string